Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

Oncogene
K CaoY Shi

Abstract

The poor efficacy of the in vivo anti-tumor immune response has been partially attributed to ineffective T-cell responses mounted against the tumor. Fas-FasL-dependent activation-induced cell death (AICD) of T cells is believed to be a major contributor to compromised anti-tumor immunity. The molecular mechanisms of AICD are well-investigated, yet the possibility of regulating AICD for cancer therapy remains to be explored. In this study, we show that histone deacetylase inhibitors (HDACIs) can inhibit apoptosis of CD4(+) T cells within the tumor, thereby enhancing anti-tumor immune responses and suppressing melanoma growth. This inhibitory effect is specific for AICD through suppressing NFAT1-regulated FasL expression on activated CD4(+) T cells. In gld/gld mice with mutation in FasL, the beneficial effect of HDACIs on AICD of infiltrating CD4(+) T cells is not seen, confirming the critical role of FasL regulation in the anti-tumor effect of HDACIs. Importantly, we found that the co-administration of HDACIs and anti-CTLA4 could further enhance the infiltration of CD4(+) T cells and achieve a synergistic therapeutic effect on tumor. Therefore, our study demonstrates that the modulation of AICD of tumor-infiltrating CD4(+) T cel...Continue Reading

References

Dec 21, 1989·The New England Journal of Medicine·B D Kahan
Jan 19, 1984·The New England Journal of Medicine·R M MerionR Y Calne
Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Feb 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D L Vaux
Jan 1, 1996·Annual Review of Immunology·D Cantrell
Mar 1, 1996·Trends in Biochemical Sciences·M D Jacobson
Jan 1, 1997·Annual Review of Immunology·A RaoP G Hogan
Dec 8, 1998·The Journal of Experimental Medicine·M MüllerP H Krammer
Mar 30, 1999·Experimental Cell Research·M Jäättelä
Aug 15, 2002·Cancer Letters·Toshiyuki TanakaHidetoshi Yamanaka
Sep 3, 2002·Cancer Cell·Heather L MaeckerAmato J Giaccia
May 20, 2003·Immunological Reviews·Douglas R GreenMichael Pinkoski
Sep 3, 2003·Nature Reviews. Cancer·Mark E Dudley, Steven A Rosenberg
Nov 11, 2003·BMC Cancer·José Manuel Afonso MoreiraPoul Sørensen
Dec 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yufang ShaoXuejun Jiang
Mar 2, 2005·Cell Cycle·Paul A Marks, Xuejun Jiang
Oct 14, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Timothy A Bolger, Tso-Pang Yao
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Feb 1, 2006·Laboratory Investigation; a Journal of Technical Methods and Pathology·Ping Yu, Yang-Xin Fu
Feb 9, 2006·Current Opinion in Immunology·Karl S PeggsJames P Allison
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Dec 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Santhakumar Manicassamy, Zuoming Sun
May 4, 2007·The Journal of Clinical Investigation·Jeremy B Swann, Mark J Smyth
Jun 20, 2007·Cell Research·Guangwu Xu, Yufang Shi
Oct 1, 2008·Cancer Letters·Olaf WittIna Oehme
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jun 7, 2012·The Journal of Biological Chemistry·Feiyan LiuKebin Liu
Jan 3, 2014·The Journal of Clinical Investigation·Alison C West, Ricky W Johnstone

❮ Previous
Next ❯

Citations

Jun 24, 2015·Nutrients·Lorenza DíazIsabel Méndez
Dec 19, 2015·Cancer Cell·Lorenzo GalluzziGuido Kroemer
Feb 26, 2016·ACS Chemical Biology·Jeffrey E LópezCarol A Fierke
Jun 28, 2016·Nature Reviews. Genetics·C David Allis, Thomas Jenuwein
Nov 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Bonavida, S Chouaib
Jan 25, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Manson, R Houot
Dec 1, 2017·Immunotherapy·Tyler R McCawDonald J Buchsbaum
Oct 14, 2017·Immunological Reviews·Yuting MaHeng Yang
May 30, 2020·Cell Research·Yonina R Murciano-GoroffJedd D Wolchok
Jun 21, 2020·International Journal of Molecular Sciences·Sena KimJaebok Choi
Sep 8, 2016·Cold Spring Harbor Perspectives in Medicine·Yixuan Li, Edward Seto
Nov 9, 2018·Cancer Immunology, Immunotherapy : CII·Jingjing ZhuBenoit J Van den Eynde
Aug 2, 2017·Current Medicinal Chemistry·Li-Ming Zhao, Jie-Huan Zhang
Dec 16, 2019·Cellular and Molecular Life Sciences : CMLS·Ziqiang WangWeiren Huang
Mar 13, 2020·Protein & Cell·Xiaoguang WangJing H Wang
Jun 3, 2017·Clinical Epigenetics·Roberta MazzoneSergio Valente
Nov 14, 2019·Cancer Immunology, Immunotherapy : CII·Tyler R McCawTroy D Randall
Feb 23, 2021·Frontiers in Oncology·Jianyu ChenYuhua Li
May 22, 2021·Human Vaccines & Immunotherapeutics·Andrew GeorgeWafik S El-Deiry
Jun 29, 2021·Frontiers in Oncology·Claudia TrojanielloPaolo A Ascierto
Jul 16, 2021·Frontiers in Immunology·Elodie RenaudeOlivier Adotévi
Apr 4, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xinyuan LeiSong Fan
Jul 25, 2021·Cancers·Dimitris Karagiannis, Theodoros Rampias

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
density gradient centrifugation

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.